[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"interstitial-lung-disease-ild\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:interstitial-lung-disease-ild":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,31,0,25,[9,68,93,122,156,189,211,232,255,290,318,343,370,392,420,446,474,498,529,554,575,595,618,646,672],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100630072","optimizing-the-diagnostic-journey-in-interstitial-lung-disease-the-optimize-ild-1-trial-100630072",false,"NCT07482917","Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial","OPTIMIZE-ILD-1: A Randomized, Pragmatic, Parallel-Group Trial Evaluating the Impact of an Optimized Diagnostic Circuit on Time to Diagnosis in Patients With Suspected Interstitial Lung Disease","OPTIMIZE-ILD-1","Inclusion Criteria:\n\n* Age 18 years or older.\n* Referral for suspected or undiagnosed interstitial lung disease (ILD).\n* At least one of the following:\n\n  * A finding suggestive of ILD (such as reticulation, ground-glass opacities, traction bronchiectasis or honeycombing) not attributable to another disease, on a CT available at referral that includes the lung parenchyma, regardless of its indication; or\n  * Persistent or progressive shortness of breath or chronic cough not attributable to another disease, accompanied by at least one of the following: an interstitial or reticular pattern on chest radiograph; reduced forced vital capacity; persistent bibasilar crackles or digital clubbing; a relevant environmental or occupational exposure, autoimmune disease, or suspected drug or radiation toxicity; or a first-degree family history of ILD.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Complete ILD diagnostic work-up already performed (chest CT plus full pulmonary function testing including six-minute walk test plus complete ILD laboratory panel).\n* Established diagnosis of ILD previously assigned by another center or specialist.\n* Clinical instability or acute illness that would prevent reliable completion of diagnostic procedures (e.g., respiratory infection, suspected acute ILD exacerbation, acute heart failure).\n* Acute iatrogenic pneumonitis (drug-, chemotherapy- or radiation-induced) with a clear temporal relationship to the offending agent.\n* Medical, functional, psychiatric or logistical limitations that, in the investigators' opinion, would interfere with the diagnostic process or data collection.\n* Participation in another interventional clinical trial that may alter the frequency or timing of diagnostic procedures.\n* Cognitive impairment that prevents informed consent or completion of study questionnaires.\n* Refusal to participate or to allow the collection or use of clinical data.","ALL","18 Years",{"count":21,"type":22},92,"ESTIMATED","INTERVENTIONAL",[25],"NA","The OPTIMIZE-ILD-1 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated diagnostic pathway on patients with suspected interstitial lung disease (ILD). In routine clinical practice, diagnostic workflows for ILD are frequently fragmented, involving multiple independent appointments that can lead to significant delays and increased burden for patients and caregivers. This study compares the standard diagnostic pathway against an optimized circuit where core diagnostic procedures-such as high-resolution CT, pulmonary function tests, and laboratory panels-are pre-bundled and scheduled within a coordinated and compressed timeframe.\n\nAll eligible patients referred for suspected ILD are included consecutively to ensure a pragmatic, real-world representation of the referral population. The primary objective is to measure the time to diagnostic communication, defined as the duration from randomization to the date the patient is formally informed of the final diagnosis following a multidisciplinary team (MDT) consensus. Secondary objectives include assessing the time to MDT diagnosis, the time to treatment initiation (when clinically indicated), socioeconomic cost-burden, and the environmental carbon footprint of the diagnostic journey. Furthermore, the study evaluates health-related quality of life, psychological distress, and clinical frailty, while exploring factors such as language proficiency as determinants of diagnostic equity. Caregiver-related outcomes, including burden and experience measures, are contingent upon the presence of a primary caregiver and the provision of their independent informed consent.\n\nThe design of this protocol was informed by a patient focus group and is officially endorsed by the 'AIRE' Associació Catalana de Malalts i Trasplantats Pulmonars, ensuring a patient-centered approach that prioritizes the diagnostic journey's efficiency and human impact.",[28,29,30,31,32],"Interstitial Lung Disease (ILD)","Suspected Interstitial Lung Disease","Fibrotic Interstitial Lung Disease","Idiopathic Pulmonary Fibrosis (IPF)","Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)",[34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54],"Interstitial Lung Disease","ILD","Suspected ILD","Pulmonary Fibrosis","Idiopathic Pulmonary Fibrosis","Connective Tissue Disease-ILD","IPF","Diagnostic Pathway","Diagnostic Delay","Multidisciplinary Discussion","One-Day ILD Clinic","Time to Diagnosis","Time to Treatment Initiation","Organizational Intervention","Health Services Research","Diagnostic Workflow Optimization","Patient Experience","Quality of Life","Pulmonary Function Tests","High-Resolution CT","Carbon Footprint","RECRUITING","2026-06-30",{"date":58,"type":59},"2026-07-02","ACTUAL",{"date":61,"type":59},"2026-03-09",{"date":63,"type":22},"2028-03-01",{"name":65,"class":66},"Hospital de Granollers","OTHER",1,{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":92},"100586150","multi-site-study-of-the-clinical-impact-of-an-ai-assisted-approach-to-referring-patients-with-interstitial-lung-disease-for-diagnostic-evaluation-of-pulmonary-hypertension-100586150","NCT06911632","Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension","MOMENTOUS Study (iMpact Of an Ecg ai ModEl oN The Diagnosis Of pUlmonary hypertenSion)","MOMENTOUS","Inclusion Criteria:\n\n* 18 years or older at the time of consent\n* A known diagnosis of interstitial lung disease\n* Diffusing capacity for carbon monoxide (DLCO) \\\u003C30% predicted, collected within 3 months prior to consent\n* Willing and able to provide informed consent and undergo all study-specific procedures, including echo and RHC, if required\n\nExclusion Criteria:\n\n* A known diagnosis of pulmonary hypertension (including patients prescribed a therapy specifically for pulmonary arterial hypertension (PAH))\n* A RHC was completed within the previous 1 year or ordered and not yet completed at the time of consent\n* LV ejection fraction ≤ 40% on most recent echo or cardiac MRI, if available\n* Unclassifiable Tempus PH ECG risk result after up to 2 ECG acquisitions\n* A contraindication to RHC exists (for example, pregnancy or mechanical right heart valve)\n* Physician decision that if a patient is directed to RHC by the study protocol, the potential risks of RHC outweigh the potential benefits\n* There is a severe concomitant illness limiting life expectancy to less than 6 months (at the discretion of the investigator)\n* There is a medical or social factor that makes the patient a poor candidate for the study and\u002For unlikely to be able to comply with the study protocol or complete study procedures (at the discretion of the investigator)",{"count":77,"type":22},900,[25],"MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.",[81,28],"Pulmonary Hypertension",[81,83],"Interstitial lung disease (ILD)",{"date":58,"type":59},{"date":86,"type":59},"2025-07-23",{"date":88,"type":22},"2028-07",{"name":90,"class":91},"Tempus AI","INDUSTRY",30,{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":121},"100644283","tele-pulmonary-rehabilitation-for-patients-with-chronic-lung-diseases-100644283","NCT07666841","Tele-Pulmonary Rehabilitation For Patients With Chronic Lung Diseases","Tele-Pulmonary Rehabilitation to Improve Adherence and Management of Patients With Chronic Lung Diseases","TELE-PRIME","Inclusion Criteria:\n\n1. Patients meeting the Israeli Health Basket criteria for reimbursement of pulmonary rehabilitation (PR), including one of the following conditions:\n\n   * COPD with an FEV1 below 50% or with severe exacerbation (hospitalization) in the previous year or two moderate exacerbations in the previous year.\n   * Interstitial lung disease with an FVC below 80% or a DLCO below 60%.\n   * Bronchiectasis with at least two exacerbations in the past year or at least one hospitalization, and an FEV1 below 80%.\n   * Pulmonary arterial hypertension.\n2. Willingness to initiate a PR or Tele-PR (TPR) programs.\n3. Ability to perform the TPR program or traditional PR activities as assessed by a member of the study team prior to enrollment.\n4. Agree to participate, with signed informed consent.\n\nExclusion Criteria:\n\n1. Uncontrolled comorbidity (e.g uncontrolled congestive heart failure)\n2. Inability to operate the mobile application.\n3. Without a mobile device or computer.\n4. A hospitalization in the 2-months prior to randomization.\n5. Completed PR program in the last 12 months.\n6. Inability to complete 10 repetitions in the 1-minute sit-to-stand test or 5-second single-leg stance\n7. Pregnancy\n8. Inability to provide informed consent due to impaired decision-making capacity, as determined by the study's capacity assessment.",{"count":102,"type":22},90,[25],"Pulmonary rehabilitation is a key treatment for lung diseases, but many patients struggle to attend sessions due to travel distances, physical limitations, or logistical barriers. The purpose of this study is to evaluate whether a tele-pulmonary rehabilitation (TPR) program can improve the rates of treatment initiation and adherence among patients with chronic lung diseases compared to traditional, center-based pulmonary rehabilitation. Additionally, the study will assess improvements in quality of life, physical symptoms, and safety in both groups.\n\nThis study will enroll 90 patients from two medical centers in Israel (Tel Aviv and Barzilai). Participants will be randomly assigned to one of two groups:\n\n1. The control group will receive usual care with a referral by a pulmonologist to standard pulmonary rehabilitation at a medical center.\n2. The intervention group will participate in a supervised remote tele-rehabilitation program using a dedicated application and remote monitoring.",[106,107,108,109,28],"COPD (Chronic Obstructive Pulmonary Disease)","Rehabilitation","Bronchiectasis Adult","Pulmonary Arterial Hypertension (PAH)","NOT_YET_RECRUITING","2026-06-18",{"date":113,"type":59},"2026-06-24",{"date":115,"type":22},"2026-07-01",{"date":117,"type":22},"2028-12-31",{"name":119,"class":120},"Tel-Aviv Sourasky Medical Center","OTHER_GOV",2,{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":130,"sex":18,"minAge":19,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":135,"conditions":136,"keywords":141,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":154,"locationsCount":67},"100642831","breathlessness-perceptions-within-respiratory-diseases-100642831","NCT07648082","Breathlessness Perceptions Within Respiratory Diseases","Exploring Differences in Breathlessness Perceptions Within Respiratory Diseases","BiRD","Inclusion Criteria:\n\n* • Aged 18 or over up to 100\n\n  * Known respiratory diagnosis\\* OR Healthy control\\*\\*\n  * Ongoing symptoms of breathlessness defined as ≥2 MRC dyspnoea scale\n  * Able to communicate in English\n  * Able to attend two study visits\n  * Able to provide written informed consent\n\n    * Known respiratory diagnosis could include, but is not limited to, COPD, Asthma, Bronchiectasis or ILD.\n    * Healthy controls are required to have an absence of a functionally limiting condition such as respiratory, cardiovascular, or musculoskeletal.\n\nExclusion Criteria:\n\n* • Unstable disease or undergoing investigations for unexplained symptoms\n\n  * Undergone a surgery within past six weeks\n  * Contraindications for exercise outlined by ACSM guidelines (Unstable CVD, hypertension etc)\n  * BMI ≥ 35kg\u002Fm2\n  * Unable to communicate in English\n  * Unable to provide written informed consent\n  * Unable to abstain from smoking for 8 hours prior to testing",true,"100 Years",{"count":133,"type":22},75,"OBSERVATIONAL","Breathlessness is a complex symptom that results in poor quality of life, increased hospitalisations and increased mortality. Breathlessness is influenced by physiological, psychological and functional factors but these are poorly explored. There are also unexplored phenomenon's such as breathing pattern. Therefore, this study aims to understand the influences of physiology, psychology, function and breathing pattern on health related quality of life in those with a respiratory disease compared to healthy controls. This project is a cross-sectional cohort study including those with a known respiratory disease and experiencing breathlessness, compared to non-breathless healthy controls. The investigators will measure your physiology through spirometry (a breathing test that tells us about their lung function), psychology through questionnaires, function through an exercise test and breathing pattern using opto-electrictronic plethysmography (markers are placed on your chest to see how participants breathe while exercising). This will be conducted over two visits. The investigators will recruit participants from clinics at the University Hospitals of Leicester NHS Trust. The investigators are aiming to recruit 50 participants with a respiratory disease and 25 healthy controls. The results of this study will help us understand breathlessness in more detail in order to be able to develop better treatments.",[137,138,28,139,140],"Chronic Obstructive Pulmonary Disease (COPD)","Asthma (Diagnosis)","Bronchiectasis","Breathing Pattern Disorder",[142,143,144,145,146,147],"Breathlessness","OEP","Cardiopulmonary Exercise Testing","Respiratory diseases","Heart rate variability","Breathing patterns","2026-06-10",{"date":150,"type":59},"2026-06-15",{"date":152,"type":59},"2025-06-06",{"date":115,"type":22},{"name":155,"class":66},"University Hospitals, Leicester",{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":23,"phases":166,"briefSummary":167,"conditions":168,"keywords":173,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":67},"100606268","hypnosis-on-breathlessness-mastery-in-patients-with-persistent-dyspnea-100606268","NCT07173348","Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea","Effectiveness of Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea: a Randomised Controlled Trial","HYPNEA","Inclusion Criteria:\n\n* Patients aged ≥ 18 years and\n* Primary diagnosis of metastatic cancer, COPD stage at least B or E, ILD, or CHF and\n* Dyspnea stage NYHA ≥ II or mMRC ≥ 2\n\nExclusion Criteria:\n\n* Have had hypnosis treatment in the last 12 months\n* Have an estimated life expectancy of less than 6 months\n* Have participated in pulmonary rehabilitation in the last 6 months\n* Have been hospitalised in the last month (30 days)\n* Are unable to come to the hospital for 3 outpatient consultations (1 every two weeks)\n* Have a condition that would interfere with their ability to respond to the questionnaires (i.e. cognitive impairment, hearing impairment, etc.)\n* Are not eligible for a hypnosis session due to a psychiatric disorder",{"count":165,"type":22},82,[25],"Persistent dyspnea is a debilitating symptom, that is common and difficult to treat. This symptom is found in many different diseases including chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), chronic heart failure (CHF), and metastatic cancer. Dyspnea is associated with many other symptoms, including anxiety, depression, and fatigue and is responsible for a significant reduction in quality of life. To date, only opiates are recommended for the pharmacological treatment of persistent dyspnea.\n\nThe effectiveness of hypnosis is well known in the treatment of anxiety and delivered to patients suffering from chronic dyspnea for this reason. One randomised controlled study has shown that a single 20-minute mindfulness sessions could significantly reduce general symptom burden and have a significant impact on anxiety and depression in palliative care patients. Furthermore, the intervention had no negative side effects.\n\nOur aim is to evaluate the effectiveness of three hypnosis sessions on breathlessness mastery in patients with persistent dyspnea, using as a primary outcome the mastery domain of a validated tool, the Chronic Respiratory Questionnaire (CRQ).",[169,28,170,171,172],"Cancer (With or Without Metastasis)","Chronic Heart Failure (CHF)","COPD","Dyspnea",[174,175,176,177,34,178,179],"Hypnosis","Persistant dyspnea","Cancer with metastasis","Chronic Obstructive Pulmonary Disease","Chronic Heart Failure","Palliative Care","2026-06-05",{"date":182,"type":59},"2026-06-08",{"date":184,"type":59},"2026-04-01",{"date":186,"type":22},"2028-04-01",{"name":188,"class":66},"University Hospital, Geneva",{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":130,"sex":18,"minAge":195,"maxAge":4,"enrollmentInfo":196,"targetDuration":198,"studyType":134,"phases":4,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":4},"100643772","a-study-to-evaluate-the-diagnostic-performance-of-portable-oscillometry-across-chronic-respiratory-diseases-100643772","NCT07631507","A Study to Evaluate the Diagnostic Performance of Portable Oscillometry Across Chronic Respiratory Diseases","Inclusion Criteria:\n\n* COPD group:\n\n  * Age：≥40\n  * Suspected COPD：COPD-SQ≥16，and no evidence of airflow limitation after bronchodilators\n  * Confirmed COPD：According to the diagnostic criteria in the 2021 Revised Edition of the Chinese Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease and the 2026 GOLD Report, a diagnosis requires the presence of symptoms (such as dyspnea, chronic cough, or sputum production), a history of exposure to risk factors (e.g., smoking, biomass fuels, occupational exposures, or air pollution), evidence of persistent airflow limitation (post-bronchodilator FEV1\u002FFVC \\\u003C 0.70), and the exclusion of alternative diagnoses.\n  * Exclude acute exacerbation within the last month Asthma group：\n  * Age：≥3\n  * Suspected asthma：Patients with chronic respiratory symptoms but no evidence of variable airflow limitation\n  * Confirmed asthma：According to the diagnostic criteria in the 2024 Chinese Guidelines for the Prevention and Treatment of Bronchial Asthma and the 2025 GINA Report, diagnosis requires the presence of recurrent symptoms (such as wheezing, shortness of breath, chest tightness, and cough) that resolve spontaneously or with treatment; evidence of variable airflow limitation (e.g., a positive bronchodilator reversibility test, a positive bronchial provocation test, or an average daily diurnal PEF variability of \\>10% over at least 7 consecutive days); and the exclusion of alternative diagnoses.\n\nHealthy subjects:\n\n* Age ≥ 3 (See Table 1 for details)\n* No respiratory symptoms（cough, expectoration, shortness of breath, wheezing, etc）\n* No history of serious cardiopulmonary or other systemic diseases, especially no history of respiratory diseases and surgery\n* No history of respiratory infection within the past 4 weeks; non-smoker or total lifetime smoking \\\u003C 100 cigarettes\n* No history of occupational exposure to harmful gases or dust, or serious pollution of the work or living environment\n* No abnormalities on chest physical examination\n* No abnormalities were found on chest imaging (X-ray, CT) records within the past year.\n* Body mass index within the normal range (18.5\\~24.9) Confirmed Bronchiectasis Group：\n* Age ≥ 3 years\n* Clinical history consistent with bronchiectasis, confirmed by CT scan\n* No other concurrent or accompanying respiratory diseases at present Confirmed ILD Group：\n* Age ≥ 3 years\n* Fibrotic interstitial lung disease: HRCT scan shows fibrotic lung disease, defined as reticular abnormalities and traction bronchiectasis with or without honeycombing, and the disease extent \\> 10%; or lung tissue biopsy indicates fibrotic interstitial changes\n* No other concurrent or accompanying respiratory diseases at present Confirmed Upper Airway Obstruction Group：\n* Age ≥ 3 years, gender not restricted\n* History of upper airway inflammation, injury, endotracheal intubation or tracheotomy, burns, foreign body aspiration, tracheal tumor, or other conditions that can cause large airway obstruction\n* Clinical manifestations are mainly dyspnea and shortness of breath, which are significantly aggravated after activity, and sometimes symptom exacerbation is related to body position\n* Pulmonary function test shows significant limitation of inspiratory or expiratory flow in the F-V curve, presenting a characteristic plateau pattern\n* At least one of the following evidences: chest CT scan or upper airway three-dimensional reconstruction confirms upper airway stenosis; laryngoscopy or bronchoscopy reveals tracheal\u002Fbronchial wall thickening and\u002For stenosis, intratracheal nodules or neoplasms, tumor infiltration, tracheal mucosal congestion, tracheal cartilage collapse, etc\n\nExclusion Criteria:\n\n* • Contraindications for oscillometry testing and spirometry testing: Oscillometry testing: Severe and intolerable dyspnea, acute exacerbation of respiratory infection, uncontrolled epilepsy, oral or facial diseases or deformities preventing proper latching, tympanic membrane perforation, need for continuous oxygen therapy, indwelling gastric tube, tracheotomy with inability to close the tube, currently undergoing artificial ventilation and unable to temporarily stop the procedure; Spirometry testing: Recent severe cardiovascular disease, epileptic seizures, uncontrolled hypertension, aortic aneurysm, severe hyperthyroidism, heart rate \\>120 bpm, tympanic membrane perforation, other respiratory infectious diseases, etc.;\n\n  * Other respiratory diseases that affect lung function results： such as lung cancer, pneumonia, active pulmonary tuberculosis, pulmonary embolism, etc.; Recent surgical history that affects lung function results, including open-chest surgery, pleural effusion surgery, etc.;\n  * Poor cooperation during basic lung function tests, failing to meet quality control requirements;\n  * Breastfeeding women;\n  * Participants deemed unlikely by the researcher to comply with research procedures and restrictions.","3 Years",{"count":197,"type":22},4000,"1 Day","This is a prospective, multicenter, observational cohort study enrolling approximately 4,000 subjects across about 50 centers, including patients with COPD (confirmed and suspected), asthma (confirmed and suspected), bronchiectasis, interstitial lung disease (ILD), upper airway obstruction (UAO), and healthy controls. Participants will undergo standardized clinical assessments, cough search, FENO, ETCO2, impulse oscillometry, spirometry, and\u002For bronchodilator test, and\u002For bronchoprovocation test, and\u002For diffusion capacity test at a single baseline visit, with no investigational intervention or treatment assignment. The primary objective is to evaluate the diagnostic performance of portable impulse oscillometry in Chronic respiratory diseases and to develop an artificial intelligence diagnostic model for COPD based on oscillometry. The study duration per subject is limited to the screening\u002Fbaseline visit, with no follow-up visits planned.",[171,138,201,139,28,202],"Chronic Respiratory Diseases","Upper Airway Obstruction","2026-06-02",{"date":182,"type":59},{"date":206,"type":22},"2026-07-30",{"date":208,"type":22},"2027-08-30",{"name":210,"class":66},"The First Affiliated Hospital of Guangzhou Medical University",{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":220,"briefSummary":221,"conditions":222,"keywords":223,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":228,"leadSponsor":230,"locationsCount":4},"100638071","vr-assisted-exercise-for-symptom-management-and-rehabilitation-in-interstitial-lung-disease-100638071","NCT07628725","VR-Assisted Exercise for Symptom Management and Rehabilitation in Interstitial Lung Disease","Virtual Reality-Assisted Breathing Exercises to Support Symptom Management and Rehabilitation in Interstitial Lung Diseases","Inclusion Criteria:\n\n* ≥ 18 years old\n* able to understand English\n* diagnosed with Interstitial Lung Disease (ILD)\n\nExclusion Criteria:\n\n* experiencing acute exacerbation of their condition\n* being unable to provide informed consent\n* being unable to participate in a VR-based intervention",{"count":219,"type":22},32,[25],"This project aims to create and improve a VR-based breathing exercise program for patients with interstitial lung diseases (ILDs). It involves three phases: (1) developing an interactive VR application with guided breathing exercises and real-time biofeedback tailored for ILD patients, (2) testing its feasibility by evaluating usability and acceptability, and (3) refining the intervention based on feedback from the feasibility study.",[28],[34,224,225],"Telerehabilitation","VR-based",{"date":180,"type":59},{"date":150,"type":22},{"date":229,"type":22},"2026-12-15",{"name":231,"class":66},"University of Manitoba",{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":239,"enrollmentInfo":240,"targetDuration":4,"studyType":23,"phases":242,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":67},"100624230","a-study-on-the-efficacy-and-safety-of-jak-inhibitors-versus-calcineurin-inhibitors-as-initial-therapy-for-interstitial-lung-disease-associated-with-antisynthetase-syndrome-100624230","NCT07406932","A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome","JAKCNIASSILD","Inclusion Criteria:\n\n* Age 18 to 75 years.\n* Meet the 2017 EULAR\u002FACR diagnostic criteria for Anti-synthetase Syndrome (ASS).\n* Presence of Interstitial Lung Disease (ILD) confirmed by High-Resolution Computed Tomography (HRCT).\n* Active disease requiring initiation or intensification of immunosuppressive therapy, with no prior use of glucocorticoids, immunosuppressants, or biologics.\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Diagnosis of Rapidly Progressive ILD (RP-ILD), defined as worsening dyspnea within 1 month and PaO2\u002FFiO2 ratio \\\u003C 250 mmHg.\n* Active uncontrolled severe infection, malignancy, or major organ failure.\n* Pregnancy or lactation.\n* Contraindications to the study drugs.\n* Concurrent use of other immunosuppressants or biologics.","75 Years",{"count":241,"type":22},80,[25],"This study is a prospective investigation comparing the efficacy and safety of Janus kinase inhibitors versus calcineurin inhibitors as initial therapy for interstitial lung disease associated with antisynthetase syndrome. The goal is to determine which treatment is more effective at improving lung function and preventing disease progression, while comparing their safety profiles. The findings will help provide clearer treatment guidance for doctors and patients.",[245,28],"Antisynthetase Syndrome","2026-05-31",{"date":248,"type":59},"2026-06-03",{"date":250,"type":22},"2026-05-18",{"date":252,"type":22},"2027-07-01",{"name":254,"class":66},"China-Japan Friendship Hospital",{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":265,"conditions":266,"keywords":273,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":289},"100640851","safety-of-bronchoscopy-in-patients-with-interstitial-lung-disease-100640851","NCT07627594","Safety of Bronchoscopy in Patients With Interstitial Lung Disease","Safety of Bronchoscopy in Patients With Interstitial Lung Disease: A Prospective, Observational, Multicentre, International Study","SaBrILD","Inclusion Criteria:\n\n* Consecutive adult (≥18 years old) patients with suspected or confirmed ILD who need to undergo bronchoscopy as part of their routine clinical practice,\n* Patients able to understand and sign an informed consent\n\nExclusion Criteria:\n\n* Patients who refused the study partecipation;\n* Patients with contraindications to bronchoscopy",{"count":264,"type":22},427,"Bronchoscopy is an essential technique, routinely used in the differential diagnosis workup of many Interstitial Lung Diseases (ILDs) and in referral centres is a common procedure. Bronchoalveolar lavage (BAL), bronchial and transbronchial biopsies with forceps and cryoprobes, and lymph node sampling with endosonography represent the most used sampling techniques in these patients. However, patients with ILDs refer to medical attention in a wide range of clinical conditions from mild functional impairment, with absent or few respiratory symptoms, to severe lung involvement with low exercise tolerance and\u002For chronic respiratory failure. In these patients, a balance between benefits and risk, i.e. to the safety and diagnostic utility of bronchoscopy should be always carefully evaluated. Moreover, there is a wide variability in adverse events entity and frequency depending by procedures performed during bronchoscopy.\n\nDespite its crucial utility, only few data are available in the literature on the safety of bronchoscopy in patients with ILDs and limited data on the utility and safety of this sampling technique are present in patients with AE-ILDs.\n\nThe primary aim of this study is to assess the overall rate of complications occurring within 24 hours after bronchoscopy. Study rate and type of complications occurring during the endoscopic procedure, within 30 days after bronchoscopy, in patients with AE-ILDs, among fibrotic Vs non-fibrotic ILD, and according to each employed sampling technique will be also recorded.",[28,267,268,269,270,271,272,37],"Bronchoscopy","Bronchoalveolar Lavage (BAL)","Acute Exacerbation","Cryobiopsy","Transbronchial Biopsy","Endosonography",[35,274,275,276,277,278,279],"BAL","acute exacerbation","cryobiopsy","transbronchial biopsy","interstitial lung disease","pulmonary fibrosis","2026-05-29",{"date":282,"type":59},"2026-06-04",{"date":284,"type":22},"2026-06-01",{"date":286,"type":22},"2028-05-30",{"name":288,"class":66},"University of Milan",11,{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":130,"sex":18,"minAge":19,"maxAge":297,"enrollmentInfo":298,"targetDuration":300,"studyType":134,"phases":4,"briefSummary":301,"conditions":302,"keywords":303,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":317},"100637855","better-tests--improving-diagnostic-accuracy-and-prognostication-in-interstitial-lung-diseases-100637855","NCT07615504","Better Tests- Improving Diagnostic Accuracy and Prognostication in Interstitial Lung Diseases","Better Tests","Inclusion Criteria:\n\nTo participate subjects will either have to be active Pigeon Fanciers, or will be either attending ILD clinics for management of their interstitial lung disease or will present acutely to hospital services with severe respiratory failure due to ILD.\n\nExclusion Criteria:\n\nUnable to provide informed consent","90 Years",{"count":299,"type":22},750,"5 Years","Patients with interstitial lung diseases (ILD) suffer significant delays in obtaining a diagnosis, and objective evidence of support for immunosuppressive therapies, due to weaknesses in the diagnostic tests available in ILD clinics.\n\nThis project will assess several non-invasive assessments, focusing on blood and breath based sampling, to identify candidate tests that may translate through to routine clinical use. The tests being assessed will be initially employed in Pigeon Fanciers, a group recognised to be at high risk of developing ILD compared to age matched controls, due to their regular exposure to a known cause of ILD. Candidate tests will also be assessed for change over time in this group. Tests which show promise will then be utilised in patients with ILD diagnoses, including those with severe respiratory failure, to assess their acceptability to patients and their ability to provide useful prognostic information, to allow powering of future definitive clinical trials.",[28],[34,304,305,306,307,308],"Lung fibrosis","Non-invasive assessment","Pigeon fanciers","Prognostication","Diagnosis","2026-05-22",{"date":280,"type":59},{"date":312,"type":59},"2026-01-17",{"date":314,"type":22},"2036-01-15",{"name":316,"class":66},"University of Dundee",3,{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":23,"phases":328,"briefSummary":329,"conditions":330,"keywords":331,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":289},"100583985","implementation-of-home-monitoring-in-patients-with-pulmonary-fibrosis-100583985","NCT06883448","Implementation of Home Monitoring in Patients With Pulmonary Fibrosis","The SUITS Study: Implementation of Home Monitoring in Patients With Pulmonary Fibrosis","SUITS","Inclusion Criteria:\n\n* A multidisciplinary ILD team diagnosis of pulmonary fibrosis according to ATS\u002FERS\u002FJRS\u002FALAT guidelines;\n* Adults (=\u002F\\>18 years).\n\nExclusion Criteria:\n\n* Patients who are not able to speak, read and\u002For write in Dutch;\n* Patients with no access to the internet;\n* Patients with a life expectancy of less than 1 year as determined by the treating healthcare provider;\n* Patients who are or have been using a home monitoring program for PF.",{"count":327,"type":22},220,[25],"The objective of this study is to evaluate the impact of structurally replacing half of the outpatient clinic visits for patients with pulmonary fibrosis by home monitoring and video consultations on patient self-management and health(care) outcomes.",[37,28],[332,333,334],"eHealth","Hybrid care","Self-management",{"date":336,"type":59},"2026-05-27",{"date":338,"type":59},"2024-10-02",{"date":340,"type":22},"2027-09-01",{"name":342,"class":66},"Erasmus Medical Center",{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":23,"phases":353,"briefSummary":355,"conditions":356,"keywords":357,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":4},"100636838","phase-4-this-is-a-trial-designed-to-evaluate-the-combination-of-nerandomilast-with-mycophenolate-across-a-wide-variety-of-pulmonary-fibrosis-subtypes-with-the-aim-of-providing-clinicians-with-assurance-that-this-is-an-appropriate-therapeutic-combination-100636838","NCT07570888","This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination.","Nerandomilast Added to Mycophenolate for Treatment of Pulmonary Fibrosis (NERAM-PF).","NERAM-PF","Inclusion Criteria:\n\n* Any underlying pulmonary fibrosis diagnosis (excluding IPF) with ≥ 10% fibrosis on chest HRCT (performed within 1 year of screening) by volume assessment as determined by the treating physician\n* Anticipated benefit from nerandomilast therapy as determined by the treating physician (note that previous observed progression as defined in previous PPF clinical trials is not required prior to enrolment)\n* Stable dose of mycophenolate for the preceding 3 months, with a minimum total daily dose of 1,500mg for mycophenolate mofetil or 1080mg for mycophenolate sodium\n* Clinically stable for the preceding 6 weeks (did not require addition of corticosteroids for AE-ILD, or any other reason for urgent hospitalization).\n\nExclusion Criteria:\n\n* Diagnosis of IPF\n* Contraindication to treatment with nerandomilast as determined by the treating physician\n* FVC \\\u003C 45% or DLCO \\\u003C 25% based on last PFT (must be performed within 3 months of screening)\n* Use of systemic prednisone \\> 10 mg\u002Fday for \\> 2 weeks within 3 months of screening (initiation of prednisone during the study is permitted if considered clinically indicated in the opinion of the treating physician)\n* Use of azathioprine, cyclophosphamide, rituximab, and\u002For tocilizumab within 3 months of screening (initiation of azathioprine, cyclophosphamide, rituximab, and\u002For tocilizumab during the study is permitted if considered clinically indicated in the opinion of the treating physician)\n* Use of pirfenidone and\u002For nintedanib within 6 weeks of screening (initiation of nintedanib and\u002For pirfenidone during the study is permitted if considered clinically indicated in the opinion of the treating physician)\n* Significant emphysema (\\> 10% volume on HRCT or FEV1\u002FFVC \\\u003C lower limit of normal)\n* Expected survival \\\u003C 6 months as determined by the treating physician",{"count":352,"type":22},120,[354],"PHASE4","This is a trial designed to evaluate the combination of nerandomilast with mycophenolate across a wide variety of pulmonary fibrosis subtypes, with the aim of providing clinicians with assurance that this is an appropriate therapeutic combination.",[37,28],[279,278,358,359,360],"nerandomilast","Mycophenolate mofetil","mycophenolate sodium","2026-05-05",{"date":363,"type":59},"2026-05-11",{"date":365,"type":22},"2026-06",{"date":367,"type":22},"2027-07",{"name":369,"class":66},"University of British Columbia",{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":23,"phases":379,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":67},"100636834","phase-1-safety-and-preliminary-efficacy-of-hucmsc-evs-in-interstitial-lung-disease-100636834","NCT07570836","Safety and Preliminary Efficacy of hUCMSC-EVs in Interstitial Lung Disease","A Clinical Study to Explore the Safety and Preliminary Efficacy of Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles in the Treatment of Interstitial Lung Disease","Key Inclusion Criteria:\n\n* Age 18 years and older, regardless of gender.\n* Diagnosed with interstitial lung disease (ILD).\n* High-resolution computed tomography (HRCT) findings within 3 months prior to randomization must be consistent with interstitial pulmonary imaging changes.\n* Pulmonary function test within the protocol-defined acceptable range prior to randomization.\n* Good compliance, able to understand and cooperate with the required examinations and procedures, and willing to attend follow-up visits as scheduled.\n* Voluntary participation and signing of written informed consent form.\n\nKey Exclusion Criteria:\n\n* Inability to tolerate nebulized inhalation therapy.\n* Requirement for oxygen supplementation \\> 15 hours per day during the screening period.\n* Allergic diathesis or a history of life-threatening drug hypersensitivity.\n* History of malignancy within 5 years.\n* Active hepatitis B, hepatitis C, or HIV infection.\n* Active systemic infection requiring antibiotic therapy.\n* Clinically significant laboratory abnormalities at screening.\n* Concomitant significant or severe respiratory disease.\n* History of psychiatric illness, epilepsy, or other central nervous system disorders.\n* Concomitant severe cardiovascular, hepatic, or renal systemic disease.\n* Pregnancy, planned pregnancy in the near future, or breastfeeding.\n* Unwillingness to use effective contraception during the study period.\n* Any condition that, in the opinion of the investigator, may increase the risk to the participant or interfere with the study outcomes.",{"count":378,"type":22},24,[380],"PHASE1","This is an exploratory, randomized, single-blind, placebo-controlled, multiple-dose, dose-escalation clinical study. The study aims to evaluate the safety and preliminary efficacy of nebulized inhalation of Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles (hUCMSC-EVs) in patients with interstitial lung disease (ILD).\n\nThis study is designed to include three sequential dose cohorts-low, medium, and high-with dose escalation proceeding in an ascending order. Eligible subjects will be enrolled and randomized sequentially, with a planned enrollment of 8 subjects per cohort. Within each cohort, subjects will be randomly assigned in a 3:1 ratio to receive either hUCMSC-EVs or saline placebo.",[28],"2026-05-01",{"date":385,"type":59},"2026-05-06",{"date":387,"type":22},"2026-04-30",{"date":389,"type":22},"2028-09-30",{"name":391,"class":66},"Shanghai Zhongshan Hospital",{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":23,"phases":402,"briefSummary":404,"conditions":405,"keywords":406,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":121},"100623565","phase-2-efficacy-of-l-menthol-on-breathlessness-in-interstitial-lung-disease-100623565","NCT07398287","Efficacy of L-menthol on Breathlessness in Interstitial Lung Disease","Effect of L-menthol on Breathlessness and Exercise Capacity in Interstitial Lung Disease: a Randomized Crossover Trial","Ment-ILD","Inclusion Criteria:\n\n* The subject has given written consent to participate in the study\n* Physician diagnosis of fibrosing ILD according to international guidelines\n* age 18 years or older\n* able to cycle\n* able to understand and talk Swedish to participate in the study procedures, as judged by the Investigators.\n\nExclusion Criteria:\n\n* Resting peripheral oxygen saturation (SpO2) \\\u003C 92%\n* hospitalization or clinical instability during the last four weeks\n* treatment with supplementary oxygen at rest or during exercise\n* contraindication to exercise testing in accordance with clinical practice guidelines\n* expected survival shorter than six months as judged by the Investigator\n* medical conditions including congestive heart failure, acute coronary artery disease, neuromuscular diseases, severe psychiatric illness, and olfaction disorder.",{"count":401,"type":22},20,[403],"PHASE2","The purpose of this study is to assess the effect of L-menthol on breathlessness and exercise capacity in patients with Interstitial lung disease (ILD).",[28],[278,407,408,409,410],"breathlessness","dyspnea","CPET","exercise","2026-04-23",{"date":413,"type":59},"2026-04-24",{"date":415,"type":59},"2026-04-13",{"date":417,"type":22},"2027-05",{"name":419,"class":66},"Region Skane",{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":23,"phases":429,"briefSummary":430,"conditions":431,"keywords":433,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":5},"100625269","phase-2-treatment-in-patients-with-advanced-non-small-cell-lung-carcinoma-and-interstitial-lung-disease-100625269","NCT07420439","Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease","Phase II Trial Assessing 1st Line and 2nd Line Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease","Inclusion Criteria for both parts:\n\n* Informed, written and signed consent: Patients must have signed and dated the written informed consent form approved by the ethics committee in accordance with the legal and institutional framework. It must have been signed before protocol-related procedures that are not part of normal patient management are performed. Patients should be willing and able to adhere to the schedule of visits, treatment and laboratory tests.\n* Patients with radiological ILDs. All cases should be presented in a multidisciplinary board dedicated to ILD to confirm eligibility. In centres without a local multidisciplinary board dedicated to ILD, the national multidisciplinary board CAPID can be used.\n* NSCLC proven histologically. Cytological evidence is allowed if a cytoblock has been prepared.\n* Age ≥ 18 years old.\n* Performance status ≤ 2.\n* Stage IIIB or IIIC non-eligible to radiation therapy or IV (8th TNM classification, UICC 2015). For other less advanced stages but rejected for any local treatment, possible inclusion discussion with the sponsor.\n* Disease measurable according to RECIST criteria 1.1 per investigator assessment.\n* Adequate biological function: Creatinine clearance ≥ 45 mL\u002Fmin (Cockroft or MDRD or CKD-epi); neutrophils ≥ 1500\u002Fmm3; platelets ≥ 100,000\u002Fmm3; Haemoglobin ≥ 9 g\u002FdL; liver enzymes\\\u003C 3x ULN except for patients with liver metastases (\\\u003C 5x ULN); total bilirubin ≤ 1.5x ULN except for patients with proven Gilbert's syndrome (≤ 5x ULN) or patients with liver metastases (≤ 3.0 mg\u002FdL).\n* Life expectancy of at least 12 weeks.\n* For female patients of childbearing potential and patients with a partner of childbearing potential, agreement (by the patient and\u002For partner) to use one or more highly effective contraceptives (failure rate \\\u003C 1% per year when used correctly and regularly) and to continue using it for 7 months after the last dose of treatment. Men should not donate their sperm for the duration of the study and for at least 7 months after the last dose of treatment. Oral contraception should always be combined with another method of contraception because of potential interactions with treatment. Patients should always use a condom.\n* Patient covered by national health insurance.\n* Protected adults may participate in the study if they can make decisions regarding their medical treatment in accordance with the guardianship judgment.\n\nInclusion Criteria for first-line part:\n\n* Patient must be treatment naive for advanced or metastatic disease. Treatment for non-metastatic stage is not considered as a line if there is a time interval of at least 6 months between the last dose of treatment for non-metastatic stage and recurrent disease.\n* ILD criteria: any type of ILD and any level of severity are allowed Inclusion criteria specific to second-line part\n* Patients must have received one but no more than one platinum-based therapy for advanced or metastatic disease. Treatment for non-metastatic stage is not considered as a line if there is a time interval of at least 6 months between the last dose of treatment for non-metastatic stage and recurrent disease.\n* ILD severity criteria: Patients with ILDs with mild to moderate alteration of pulmonary function, defined by Forced Vital Capacity (FVC) ≥ 50% of the predicted value AND DLCO≥ 35% of the of the predicted value. All cases should be presented in a multidisciplinary board dedicated to ILD to confirm eligibility. In centers without a local multidisciplinary board dedicated to ILD, the national multidisciplinary board CAPID can be used.\n* ILD type criteria: Patient with idiopathic interstitial pneumonia (including IPF and NSIP) or secondary ILDs (including hypersensitivity pneumonia, pneumoconiosis, radiation pneumonitis) could be included. Will be excluded patients with ILDs secondary to connective tissue disease, vasculitis or granulomatosis (including but not limited to granulomatosis with polyangiitis, rheumatoid arthritis, Sjogren's syndrome, scleroderma, myositis\u002Fdermatomyositis, anti-synthetase syndrome). For sarcoidosis and for Interstitial pneumonia with autoimmune features (IPAF) inclusion could be confirmed based on a case-by-case discussion with the sponsor.\n* Available results for Immunoassay including antinuclear antibodies tested by immunofluorescence, rheumatoid factor, anti-CCP, Anti-dsDNA, Anti-Ro (SS-A), Anti-La (SS-B), Anti-ribonucleoprotein, Anti-Smith, Anti-topoisomerase (Scl-70), Anti-tRNA synthetase (Jo-1, PL-7, PL-12, Anti-PM-Scl, Anti-MDA-5), ANCA.\n\nExclusion criteria for both parts\n\n* Small cell lung cancer or tumor with mixed histology including a small cell component.\n* Known EGFR activating mutation or ALK or ROS rearrangements. Inclusion of patients with any other oncogene addiction (excluding KRAS mutations) should be discussed with the sponsor on a case-by-case level.\n* History of cancer or cancer active within 3 years except those with a negligible risk of metastasis or death treated curatively (such as adequately treated cervical cancer in situ, basal or squamous cell skin cancer or ductal carcinoma in situ curatively treated. For other types of cancer, please contact the IFCT). Patients with a history of prostate cancer in the last 5 years may be included in cases of localized prostate cancer of good prognosis according to the Amico classification (≤ T2a and Gleason score ≤ 6 and PSA ≤ 10 ng\u002FmL) and if they have been treated curatively (surgery or radiotherapy ± hormone therapy, without chemotherapy).\n* Acute exacerbation of interstitial lung disease less than 6 months ago. Exclusion criteria specific to first line part\n* Previous systemic therapy (including but not limited to chemotherapy, targeted therapy, immunotherapy). Treatment for non-metastatic stage is not considered as a line if there is a time interval of at least 6 months between the last dose of treatment for non-metastatic stage and recurrent disease.\n\nExclusion criteria specific to second line part\n\n* History of severe allergy, anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins. Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the pembrolizumab\u002Fnivolumab formulation.\n* Diagnosis of interstitial lung disease with manifestations of autoimmunity (IPAF) according to ATS\u002FERS criteria39 Inclusion may be considered on a case-by-case basis following discussion with the sponsor.\n* More than one line of treatment.\n* Any prior immunotherapy.\n* History of autoimmune disease, connective tissue disease, vasculitis or granulomatosis associated with but not limited to myasthenia gravis, myositis, autoimmune hepatitis, inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis or glomerulonephritis.\n* Diagnosis of ILDs due to connective tissue disease, vasculitis or granulomatosis including but not limited to granulomatosis with polyangiitis, rheumatoid arthritis, Sjogren's syndrome, scleroderma, myositis\u002Fdermatomyositis, anti-synthetase syndrome. For sarcoidosis and for Interstitial pneumonia with autoimmune features (IPAF) inclusion could be confirmed based on a case-by-case discussion with the sponsor.\n* Corticosteroid therapy \\> 10 mg daily oral prednisone or equivalent.\n* Immunosuppressive therapy within two weeks prior to randomization.\n* Patients who have had major surgery ≤ 3 weeks before randomization.",{"count":428,"type":22},108,[403],"Lung cancer is a leading cause of cancer-related death worldwide. Interstitial Lung Diseases are closely associated with lung cancer either as complications or comorbidities to be considered for treatment.\n\nRecently, a survey concerning the management of lung cancer in patients with ILDs was conducted by the Interstitial Lung Diseases and Thoracic Oncology Assemblies of the European Respiratory Society. Out of 494 practitioners, mostly pulmonologists, this survey showed that the majority of metastatic patients with pulmonary fibrosis would not be treated (69%), but that 25% and 31% of clinicians would offer chemotherapy or immunotherapy, respectively.\n\nThe systemic therapy is not clearly codified. There is a risk of worsening of ILDs with most of the treatments used in lung cancer including surgery, radiation therapy or certain systemic therapies. The Japanese Society of Pneumology has recently published proposals for care. However, the Asian population is unique in its incidence of ILDs and the frequency of drug toxicities and these recommendations may not be relevant for other populations. Thus, data are still needed to validate carboplatin and weekly paclitaxel as the best regimen for first-line treatment of NSCLC patients with ILD in a caucasian population.\n\nIn 2nd line setting, immune checkpoint blocker (ICB) in monotherapy or associated with chemotherapy has become an essential part of the therapeutic arsenal in advanced NSCLC. Several agents have been shown to be superior to docetaxel, following platinum-based chemotherapy failure, and have resulted in several marketing authorizations for PD-1 inhibitors (nivolumab, pembrolizumab) and PD-L1 inhibitors (atezolizumab).\n\nThe long-term benefits of using ICBs as a second-line therapy are now clear. Survival at 5 years is 10% higher than that obtained with docetaxel alone.\n\nThe safety profile is well known in particular with a risk of pulmonary toxicity. It should be noted that in most trials, patients with ILDs were not included. Therefore, we do not have trial data from these pivotal trials in patients with concomitant ILD.\n\nTwo prospective studies are available on the use of nivolumab in the second-line setting in patients with idiopathic ILDs. The first, in an Asian population, included 6 patients. It showed an interesting response rate of 50% without grade III or IV pulmonary toxicity or worsening of at 12 weeks.\n\nFollowing this, the same team proposed a multicenter phase 2 study. Included patients had mild ILDs (VCf \\>80%) and were treated with nivolumab in 2nd line. The primary objective was PFS at 6 months. 18 patients were treated. 3 patients developed toxicity leading to discontinuation of nivolumab including 2 patients with grade 2 pneumonitis. PFS at 6 months was 56%, response rate was 39% and disease control achieved for 72% of patients.\n\nIn a recent prospective study in Asia, atezolizumab was administered to patients with moderate IPF and advanced NSCLC. The study was stopped prematurely due to a high incidence of inflammatory pneumonitis.\n\nThus, data are still needed to assess the safety of ICB in NSCLC patients with ILD in second line setting.",[432,28],"Non Small Cell Lung Cancer Metastatic",[434,35,435,436],"NSCLC","chemotherapy","immunotherapy","2026-04-22",{"date":439,"type":59},"2026-04-27",{"date":441,"type":22},"2026-05-15",{"date":443,"type":22},"2028-11-15",{"name":445,"class":66},"Intergroupe Francophone de Cancerologie Thoracique",{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":453,"enrollmentInfo":454,"targetDuration":4,"studyType":23,"phases":455,"briefSummary":456,"conditions":457,"keywords":462,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":67},"100618558","phase-2-a-study-of-mosliciguat-in-combination-with-inhaled-treprostinil-in-ph-ild-100618558","NCT07333183","A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD","An Open-Label, Phase 2 Study Evaluating the Safety of Mosliciguat in Combination With Inhaled Treprostinil in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease","Inclusion Criteria:\n\n* Participants willing and able to provide informed consent\n* Participants on inhaled treprostinil\n* Participants with diagnosis of Interstitial Lung Disease (ILD). Diagnosis will be confirmed by a high-resolution computerized tomography (HR-CT) scan showing diffuse parenchymal disease. Eligible diagnosed diseases include:\n\n  1. Idiopathic interstitial pneumonia (IIP)\n  2. Chronic hypersensitivity pneumonitis\n  3. ILD associated with connective tissue disease (CTD) with a forced vital capacity (FVC) \\\u003C 70% of predicted\n* Confirmed pulmonary hypertension (PH) by right heart catheterization (RHC).\n* Ability to perform 6MWD ≥100 meters.\n\nExclusion Criteria:\n\n* Diagnosis of PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related to left-heart dysfunction), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified).\n* Exacerbation of underlying lung disease within 28 days prior to randomization.\n* Initiation of pulmonary rehabilitation within 28 days prior to randomization.\n* Receiving \\>10 L\u002Fmin of oxygen supplementation by any mode of delivery at rest at Baseline.\n* History or intolerance to or lack of efficacy with mosliciguat or sGC stimulators or activators.\n* Receipt of investigational, or experimental therapy within 42 days OR 5 half-lives prior to randomization.\n\nNote: Other inclusion and exclusion criteria may apply.","85 Years",{"count":401,"type":22},[403],"This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.",[81,28,458,459,460,461],"Lung Diseases","Vascular Diseases","Cardiovascular Diseases","Fibrosis",[463,35,464,465],"PH","6 Minute Walk Test","mosliciguat","2026-04-18",{"date":437,"type":59},{"date":469,"type":59},"2025-12-23",{"date":471,"type":22},"2028-01",{"name":473,"class":91},"Pulmovant, Inc.",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":23,"phases":482,"briefSummary":483,"conditions":484,"keywords":486,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":67},"100634439","an-initial-experience-with-the-disposable-celsio-cryocatheter-system-for-diagnostic-and-interventional-bronchoscopy-100634439","NCT07539701","An Initial Experience With the Disposable Celsio Cryocatheter System for Diagnostic and Interventional Bronchoscopy","CELSIO","Inclusion Criteria:\n\n\\- Patient undergoing a bronchoscopic procedure with planned use of a 1.7mm cryocatheter\n\nExclusion Criteria:\n\n* Patient undergoing a bronchoscopic procedure with planned use of a different size cryocatheter (eg 1.1 or 2.4mm)\n* Current pregnancy or lactation\n* Lack of free and informed consent",{"count":92,"type":22},[25],"This clinical trial is intended for patients awaiting an interventional bronchoscopy procedure where the use of a cryocatheter is considered. This type of catheter is already used in clinical practice for the treatment of certain types of bronchial obstructions, including tumors, granulomas, and for foreign bodies extractions. This catheter uses extremely cold temperatures offering unique advantages compared to heat-based technologies. Different types of reusable and single-use cryocatheters are actually available on the market. This type of device requires the use of expensive and bulky consoles operating with heavy gas tanks, resulting in high maintenance costs. A Quebec, Canada based company has developed a cryocatheter that combines procedural efficacy with practical considerations in mind. The Celsio cryocatheter operates without a console and is designed to accommodate the bronchscopist through the different types of cryogenic procedures.\n\nThis study aims to generate meaningful, real-world evidence without interfering with standard clinical care. The collected data will serve to characterize the device's performance profile, identify best practices for its use, and provide data for the design of future prospective comparative studies.",[485,28],"Lung Cancer (Diagnosis)",[487,276,488,489],"cryocathter","cryo-extraction","cryodevitalization",{"date":491,"type":59},"2026-04-20",{"date":493,"type":22},"2026-03-23",{"date":495,"type":22},"2028-03-23",{"name":497,"class":66},"Institut universitaire de cardiologie et de pneumologie de Québec, University Laval",{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":23,"phases":508,"briefSummary":509,"conditions":510,"keywords":512,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":527,"leadSponsor":528,"locationsCount":67},"100630325","optimizing-the-follow-up-journey-in-interstitial-lung-disease-the-optimize-ild-2-trial-100630325","NCT07486206","Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial","OPTIMIZE-ILD-2: A Randomized, Pragmatic, Parallel-Group Trial Evaluating the Impact of an Optimized Coordinated Follow-Up Circuit on Time Burden in Patients With Interstitial Lung Disease","OPTIMIZE-ILD-2","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Established diagnosis of interstitial lung disease (ILD).\n* Currently receiving antifibrotic therapy, immunosuppressive therapy, or both, as part of routine ILD care.\n* Under active follow-up at the participating ILD center.\n* Able to attend the required follow-up procedures included in the study visit.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Inability to complete the coordinated follow-up visit for non-medical reasons (e.g., logistical impossibility).\n* Clinical instability or acute illness interfering with planned follow-up procedures (such as respiratory infection, suspected ILD exacerbation, acute heart failure, or other acute conditions).\n* Participation in another interventional clinical trial that may alter visit frequency or follow-up structure.\n* Cognitive impairment preventing informed consent or completion of questionnaires.\n* Patient refusal to participate or refusal to allow data collection.",{"count":507,"type":22},152,[25],"The OPTIMIZE-ILD-2 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated follow-up pathway on patients with established interstitial lung disease (ILD). In routine clinical practice, follow-up workflows for ILD are frequently fragmented, requiring multiple hospital visits for pulmonary function tests, laboratory analysis, treatment administration, and consultations with various specialists, which increases the burden for both patients and caregivers. This study compares the standard follow-up care against an optimized circuit where all routine monitoring procedures and interdisciplinary consultations are pre-bundled and scheduled within a single, coordinated hospital visit.\n\nAll eligible patients under active ILD follow-up are included consecutively to ensure a pragmatic, real-world representation of the treated ILD population. The primary objective is to measure the total follow-up time burden, defined as the total home-to-home time required to complete the follow-up circuit. As a cross-sectional assessment within a longitudinal context, secondary objectives include assessing socioeconomic cost-burden, the environmental carbon footprint of the follow-up journey, health-related quality of life, and clinical frailty. Caregiver-related outcomes, including burden and experience measures, are contingent upon the presence of a primary caregiver and the provision of their independent informed consent.\n\nThe design of this protocol was informed by a patient focus group and is officially endorsed by the 'AIRE' Associació Catalana de Malalts i Trasplantats Pulmonars, ensuring a patient-centered approach that prioritizes follow-up efficiency and human impact.",[28,30,31,511,32],"Progressive Pulmonary Fibrosis",[34,35,37,38,511,513,514,515,516,517,518,519,520,44,48,521,47,52,51,50,54,522],"CTD-ILD","Fibrotic ILD","Antifibrotic Therapy","Immunosuppressive Therapy","Follow-Up Pathway","Follow-Up Care Coordination","Time Burden","Home-to-Home Time Burden","Patient-Centered Follow-Up","Multidisciplinary Care","2026-04-06",{"date":525,"type":59},"2026-04-09",{"date":61,"type":59},{"date":63,"type":22},{"name":65,"class":66},{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":535,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":537,"targetDuration":4,"studyType":23,"phases":538,"briefSummary":539,"conditions":540,"keywords":542,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":552,"locationsCount":121},"100631449","robotic-assisted-versus-conventional-bronchoscopy-for-cryobiopsy-in-the-diagnosis-of-interstitial-lung-disease-100631449","NCT07500818","Robotic-Assisted Versus Conventional Bronchoscopy for Cryobiopsy in the Diagnosis of Interstitial Lung Disease","Robotic-Assisted Versus Conventional Bronchoscopy for Cryobiopsy in the Diagnosis of Interstitial Lung Disease: A Randomized Controlled Trial","RAB-ILD-RCT","Inclusion Criteria:\n\n* Age ≥18 years\n* Clinical suspicion of interstitial lung disease requiring histological confirmation\n* Non-diagnostic HRCT pattern (e.g. probable UIP or indeterminate pattern)\n* Candidate for transbronchial lung cryobiopsy\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Definite UIP pattern on HRCT\n* Severe pulmonary hypertension\n* Severe hypoxemia contraindicating bronchoscopy\n* Coagulopathy or contraindication to biopsy\n* Pregnancy\n* Inability to provide informed consent",{"count":92,"type":22},[25],"Interstitial lung disease (ILD) often requires histopathological confirmation when high-resolution computed tomography (HRCT) findings are inconclusive. Transbronchial lung cryobiopsy has emerged as a less invasive alternative to surgical lung biopsy, but diagnostic yield remains variable and dependent on biopsy location and procedural precision.\n\nRobotic-assisted bronchoscopy (RAB) combined with cone-beam computed tomography (CBCT) may allow more precise navigation to target lung segments and potentially improve biopsy quality and diagnostic yield.\n\nThis multi-center, investigator-initiated randomized controlled trial will compare conventional bronchoscopy with 2D fluoroscopy guidance versus robotic-assisted bronchoscopy with CBCT guidance for transbronchial lung cryobiopsy in patients undergoing diagnostic evaluation for suspected interstitial lung disease.\n\nParticipants will be randomized in a 1:1 ratio to undergo either conventional bronchoscopy or robotic-assisted bronchoscopy. In both groups, four cryobiopsies will be obtained from two lung lobes using a 1.7 mm cryoprobe (en-bloc removal for both study arms).\n\nThe primary endpoint is the rate of definitive histological diagnosis as determined by a blinded multidisciplinary ILD board.",[28,541],"Lung Biopsy",[543,270,544,545,34],"Robotic-assisted Bronchoscopy","CBCT","Interventional Pulmonology","2026-03-24",{"date":548,"type":59},"2026-03-30",{"date":550,"type":59},"2026-02-01",{"date":340,"type":22},{"name":553,"class":66},"University of Zurich",{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":239,"enrollmentInfo":560,"targetDuration":4,"studyType":23,"phases":562,"briefSummary":563,"conditions":564,"keywords":565,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":572,"leadSponsor":573,"locationsCount":4},"100624548","effects-of-clinical-pilates-on-physical-and-psychosocial-outcomes-in-individuals-with-interstitial-lung-disease-100624548","NCT07411066","Effects of Clinical Pilates on Physical and Psychosocial Outcomes in Individuals With Interstitial Lung Disease","Inclusion Criteria:\n\n* Adults aged 18 to 75 years.\n* Clinically confirmed diagnosis of interstitial lung disease (ILD) by a physician.\n* Clinically stable condition (no acute exacerbation or hospitalization related to ILD within the last 4 weeks).\n* On stable medical treatment and routine follow-up.\n* Able to walk and participate in low-to-moderate intensity exercise as determined by the clinician\u002Fphysiotherapist.\n* Able to understand study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Coexisting chronic respiratory disease that may confound outcomes (e.g., COPD, uncontrolled asthma, bronchiectasis).\n* Acute exacerbation of ILD or hospitalization within the last 4 weeks.\n* Unstable cardiovascular disease or other medical conditions making exercise unsafe (e.g., unstable angina, recent myocardial infarction).\n* Severe neurological, musculoskeletal, or balance disorders limiting safe participation in exercise.\n* Pulmonary hypertension or oxygen dependency requiring unstable\u002Fhigh-flow support if judged unsafe for exercise participation by the treating clinician.\n* Current participation in another structured exercise \u002F pulmonary rehabilitation program during the study period.\n* Major psychiatric disorder or cognitive impairment interfering with participation or adherence.\n* Pregnancy.",{"count":561,"type":22},58,[25],"This study aims to investigate the effects of Clinical Pilates on physical and psychosocial outcomes in individuals with interstitial lung disease (ILD). Interstitial lung disease is a group of chronic conditions that affect lung tissue and can lead to breathing difficulties, reduced physical capacity, fatigue, and decreased quality of life.\n\nIn addition to medical treatment, exercise-based rehabilitation approaches may help individuals with ILD improve their physical function and overall well-being. Clinical Pilates is a structured exercise method that focuses on breathing control, posture, core stability, flexibility, and body awareness.\n\nParticipants in this study will be randomly assigned to either a Clinical Pilates group or a control group receiving standard care. The Clinical Pilates program will be delivered by a trained physiotherapist over several weeks through supervised sessions.\n\nThe main outcomes of this study include physical function, respiratory symptoms, quality of life, and psychological well-being. The results of this study are expected to provide evidence on whether Clinical Pilates can be an effective and safe supportive approach for pulmonary rehabilitation in individuals with interstitial lung disease.",[28],[278,566,567],"clinical pilates","pilates","2026-02-06",{"date":570,"type":59},"2026-02-13",{"date":550,"type":22},{"date":383,"type":22},{"name":574,"class":66},"Recep Tayyip Erdogan University",{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":130,"sex":18,"minAge":581,"maxAge":4,"enrollmentInfo":582,"targetDuration":4,"studyType":23,"phases":584,"briefSummary":585,"conditions":586,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":593,"locationsCount":67},"100592379","phase-1-a-study-of-the-pharmacokinetics-and-safety-of-single-dose-inhaled-rj026-in-healthy-volunteers-and-patients-with-interstitial-lung-disease-100592379","NCT06992661","A Study of the Pharmacokinetics and Safety of Single-dose Inhaled RJ026 in Healthy Volunteers and Patients With Interstitial Lung Disease","ICD patients:\n\nInclusion Criteria:\n\n1. Age ≥40 years, any gender\n2. Diagnosed or suspected ILD (IPF or CTD-ILD) based on HRCT or thin-section CT\n3. FVC ≥40% predicted, DLCO ≥40% predicted, FEV1\u002FFVC ≥0.7\n4. Able to tolerate bronchoscopy\n5. Willing to use effective contraception during study\n6. Capable of proper inhaler use\n\nExclusion Criteria:\n\n1. Pregnancy or lactation\n2. Allergy to study drug components\n3. Active respiratory infection or acute cardiopulmonary disease\n4. Abnormal liver function (ALT\u002FAST\u002FGGT \\> ULN or total bilirubin \\> ULN)\n5. Recent smoking (within 6 months) or alcohol abuse\n6. Participation in other clinical trials within 3 months\n7. Blood donation ≥400mL within 3 months\n8. HBV DNA ≥2000 IU\u002FmL or HCV RNA ≥1000 IU\u002FmL or HIV positive","40 Years",{"count":583,"type":22},84,[380],"This Phase 1 clinical trial investigates the pharmacokinetics and safety profile of single-dose inhaled RJ026 in healthy volunteers and patients with interstitial lung disease (ILD). The randomized, double-blind, dose-escalation study employs a parallel-group design with three inhaled dose cohorts (4mg, 8mg, and 12mg) and one oral comparator arm, enrolling a total of 42 patients (12 per inhaled group, 6 in oral group) and 42 healthy volunteers (12 per inhaled group, 6 in oral group). The trial features comprehensive pharmacokinetic sampling through 15 timed blood collections over 24 hours and bronchoalveolar lavage at specified intervals (1h, 6h, 12h, or 24h post-dose) to characterize both systemic and pulmonary drug exposure. The study incorporates rigorous safety monitoring including adverse event tracking, vital sign measurements, and laboratory assessments over a 7-day observation period following drug administration. Conducted at Shanghai Jiao Tong University's Ruijin Hospital over a 12-month period (July 2025-July 2026), this investigation aims to establish the foundational pharmacokinetic parameters and safety profile of RJ026 delivery in ILD patients while comparing pulmonary bioavailability against conventional oral administration.",[28,587],"Healthy Volunteers","2026-02-03",{"date":568,"type":59},{"date":591,"type":22},"2026-01-15",{"date":115,"type":22},{"name":594,"class":66},"Ruijin Hospital",{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":4,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":239,"enrollmentInfo":602,"targetDuration":4,"studyType":23,"phases":603,"briefSummary":604,"conditions":605,"keywords":606,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":67},"100617192","acute-hemodynamic-responses-to-blood-flow-restriction-aerobic-exercise-in-interstitial-lung-disease-100617192","NCT07315425","Acute Hemodynamic Responses to Blood Flow Restriction Aerobic Exercise in Interstitial Lung Disease","Investigation of the Acute Effects of Blood Flow Restriction Aerobic Exercise on Hemodynamic Responses and Muscle Oxygen in Patients With Interstitial Lung Disease","Inclusion Criteria:\n\n* Diagnosis of interstitial lung disease according to the European Respiratory Society (ERS) and American Thoracic Society (ATS) diagnostic criteria.\n* Willingness to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Presence of any acute infection at the time of the study.\n* Orthopedic or neurological conditions that may affect exercise capacity.\n* Contraindications to exercise testing according to the American College of Sports Medicine (ACSM) guidelines.\n* History of COVID-19 infection within the last three months.\n* Receiving treatments outside standard medical therapy.\n* Presence of peripheral arterial disease.\n* Presence of peripheral neuropathy.\n* Resting blood pressure greater than 160\u002F100 mmHg.\n* History of deep vein thrombosis, pulmonary embolism, or stroke.",{"count":92,"type":22},[25],"Interstitial lung diseases (ILD)impaired gas exchange and reduced lung elasticity lead to marked reductions in exercise capacity and decreased oxygen consumption due to circulatory limitations. Blood flow restriction (BFR) exercise involves applying external pressure to partially restrict venous return without entirely blocking arterial inflow. This controlled compression induces temporary hypoxic and metabolic stress, triggering high-intensity-like responses that stimulate growth hormone release, increase protein synthesis, and promote muscle hypertrophy. However, the most crucial advantage of blood flow restriction during exercise is its ability to increase muscle mass during aerobic training. IIn individuals with ILD, BFR may offer a safe and practical way to improve muscle mass and exercise capacity with minimal additional strain on the cardiovascular and musculoskeletal systems.Our study aimed to compare the acute effects of low-intensity blood flow restriction aerobic exercise training and low-intensity aerobic exercise training on hemodynamic responses and muscle oxygenation in patients with ILD. Method: 30 patients with a diagnosis of ILD being followed up will be included in the study. Our study was a randomized, crossover, triple-blind, prospective study. Assessments will be performed at the beginning of the study. On the first day, demographic data and clinical findings of the individuals will be collected. Patients will be asked questions, and their responses will be recorded in their medical records. Respiratory function, respiratory muscle strength and endurance, and peripheral muscle strength will be evaluated. 48 hours from the first day, patients' maximal exercise capacity will be assessed with a cardiopulmonary exercise test (CPET), and muscle oxygenation during CPET will be assessed with a Moxy® monitor. Respiratory muscle fatigue will be assessed with an oral pressure monitor before and after the exercise test. The assessments will be completed over two days. One week after the evaluations, patients will be randomly assigned to two groups. One group will receive low-intensity aerobic exercise training, and the other will receive low-intensity aerobic exercise training with blood flow restriction. Muscle oxygenation will be assessed during both exercise sessions, and respiratory muscle fatigue will be measured before and after each session. All participants will receive both exercise sessions.",[28],[607,34,608,609],"Blood Flow Restriction","Muscle Oxygenation","Aerobic Exercise","2026-01-31",{"date":588,"type":59},{"date":613,"type":22},"2026-02",{"date":615,"type":22},"2028-12",{"name":617,"class":66},"Gazi University",{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":623,"acronym":4,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":625,"enrollmentInfo":626,"targetDuration":4,"studyType":23,"phases":628,"briefSummary":629,"conditions":630,"keywords":632,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":644,"locationsCount":67},"100617513","phase-4-a-study-to-test-tetrandrine-tablets-for-connective-tissue-disease-related-lung-disease-100617513","NCT07319598","A Study to Test Tetrandrine Tablets for Connective Tissue Disease-Related Lung Disease","A Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Tetrandrine Tablets in Treating Interstitial Lung Disease Related to Connective Tissue Disease","Inclusion Criteria:\n\n* Patients who voluntarily participate and sign the informed consent form\n* Male or female patients aged 18-80 years (inclusive)\n* Patients meeting the diagnostic criteria for connective tissue disease-related interstitial lung disease per the 2018 Chinese Expert Consensus at screening\n* FVC ≥40% of predicted value at screening\n* Fertile male or female patients must agree to use effective contraception from signing informed consent until 3 months after the last study drug dose (Exemptions: postmenopausal women \\>50 years with amenorrhea for \\>1 year, or surgically sterilized women)\n* Patients on stable doses of prednisone (≤20 mg\u002Fday or equivalent) or immunosuppressants for at least 4 weeks prior to study entry, with dose adjustments not exceeding this during the double-blind period\n\nExclusion Criteria:\n\n* Treatment with tetrandrine or other antifibrotic drugs within 1 month before screening\n* Diabetes with fasting blood glucose greater than 11.1 mmol per L\n* Resting arterial oxygen partial pressure less than 50 mmHg\n* Active peptic ulcers or bleeding disorders\n* Tumors with expected survival less than 1 year\n* Active pulmonary tuberculosis\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 5 times the upper limit of normal (ULN) or higher, or ALT or AST 3 times ULN or higher with total bilirubin 2 times ULN or higher\n* Creatinine clearance less than 30 mL per min (per Cockcroft-Gault formula) or patients receiving dialysis\n* Known allergy to tetrandrine or its excipients\n* Severe psychological, mental, cognitive, or intellectual impairments that may affect compliance\n* Pregnant or breastfeeding women, or those planning pregnancy within 3 months after the last study drug dose\n* Participation in another clinical trial within 3 months before screening\n* Patients deemed unsuitable for the study by the investigator\n* Clinically significant environmental exposure history that may cause pulmonary fibrosis (e.g., amiodarone, asbestos, beryllium, radiation)","80 Years",{"count":627,"type":22},100,[354],"This study evaluates the efficacy and safety of tetrandrine tablets (60 mg, three times daily) compared to placebo in adult patients with connective tissue disease-related interstitial lung disease. Patients receive standard treatment (glucocorticoids and immunosuppressants) alongside the study drug or placebo for 24 weeks. The study measures changes in lung function, inflammatory markers, lung imaging, quality of life, and safety outcomes.",[28,631],"Connective Tissue Disease-associated Interstitial Lung Disease",[633,634,34,635,636],"Tetrandrine","Connective Tissue Disease","Pulmonary Function","Inflammatory Markers","2025-12-19",{"date":639,"type":59},"2026-01-06",{"date":641,"type":59},"2023-11-02",{"date":643,"type":22},"2027-01-01",{"name":645,"class":66},"Peking University Third Hospital",{"id":647,"slug":648,"hasResults":12,"nctId":649,"briefTitle":650,"officialTitle":651,"acronym":652,"eligibilityCriteria":653,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":654,"targetDuration":4,"studyType":23,"phases":656,"briefSummary":657,"conditions":658,"keywords":660,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":663,"lastUpdatePostDateStruct":664,"startDateStruct":665,"completionDateStruct":667,"leadSponsor":669,"locationsCount":671},"100563386","routine-vs-on-demand-ecmo-for-lung-transplantation-100563386","NCT06615492","Routine vs On-demand ECMO for Lung Transplantation","RoutinE Versus On-demand Intraoperative Extracorporeal Membrane Oxygenation (ECMO) During LUng TransplantatION (REVOLUTION)","REVOLUTION","Inclusion Criteria:\n\n* Patients undergoing lung transplant surgery\n\nExclusion Criteria:\n\n* Inability to provide consent for the study\n* Retransplantation\n* Multi-organ transplantation\n* Contra-indication to standard heparin anticoagulation (e.g., heparin-induced thrombocytopenia)\n* Lung transplant recipients where intraoperative cardiopulmonary support is mandatory:\n* Severe pulmonary hypertension (PH):\n\n  1. Systolic pulmonary artery pressure (PAP) ≥ 80 mm Hg on the most recent echocardiography, right heart catheterization, or pulmonary artery catheter measurement\n  2. Mean PAP ≥ 55 mm Hg on the most recent echocardiography, right heart catheterization, or pulmonary artery catheter measurement\n  3. The ratio of mean pulmonary to systemic artery pressure of \\> 0.66\n* Moderate to severe right ventricular (RV) hypokinesis or dysfunction\n* Left ventricular dysfunction: Defined as ejection fraction (LVEF) less than 45% on echocardiography, ventriculography, computed tomography (CT), or magnetic resonance imaging (MRI)\n* Patients requiring concomitant cardiac surgery: For example, significant coronary artery disease (CAD) requiring surgical grafting",{"count":655,"type":22},218,[25],"Lung transplantation is a complex procedure performed in patients with terminal lung disease. The transplant procedure stresses the patient's heart and lungs, which are already taxed by the underlying disease process. The heart-lung machine is occasionally used to support the patient and ensure adequate oxygen supply to other organs during the operation. It can be used routinely in all patients or selectively in patients who exhibit reduced oxygen supply to the remaining organs. This process, known as cardiopulmonary bypass (CPB), pumps blood out of the body to a heart-lung machine that removes carbon dioxide and returns oxygen-filled blood to the body.\n\nAlthough using the CPB increases the risk of bleeding, infection, and coagulation complications, it should still be considered in high-risk patients to compensate for more severe complications such as kidney failure and stroke caused by a lack of cardiopulmonary support. Extracorporeal membrane oxygenation (ECMO) is a recently developed CPB variation associated with fewer bleeding complications. It has recently replaced the traditional heart-lung machine as the preferred method of cardiopulmonary support during lung transplantation. Since ECMO is associated with fewer complications than standard CPB, many centers have increased their use of ECMO during lung transplantation. Some have even employed it routinely. However, there remains significant debate on how often it should be used.\n\nTherefore, the study's main objective is to compare the two approaches in lung transplantation, i.e., routine use versus selective use, and to determine if one approach is preferable to the other.",[659,28,37,106],"Respiratory Failure",[661,662],"ECMO","Lung Transplantation","2025-12-17",{"date":469,"type":59},{"date":666,"type":59},"2024-11-05",{"date":668,"type":22},"2029-01-15",{"name":670,"class":66},"Centre hospitalier de l'Université de Montréal (CHUM)",4,{"id":673,"slug":674,"hasResults":12,"nctId":675,"briefTitle":676,"officialTitle":677,"acronym":678,"eligibilityCriteria":679,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":239,"enrollmentInfo":680,"targetDuration":4,"studyType":23,"phases":682,"briefSummary":683,"conditions":684,"keywords":685,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":689,"lastUpdatePostDateStruct":690,"startDateStruct":692,"completionDateStruct":694,"leadSponsor":696,"locationsCount":67},"100616408","safety-profile-of-ultrasound-guided-transparietal-lung-biopsy-in-patients-with-diffuse-interstitial-lung-disease-100616408","NCT07305220","Safety Profile of Ultrasound-guided Transparietal Lung Biopsy in Patients With Diffuse Interstitial Lung Disease","Safety Profile Study of Ultrasound-guided Transparietal Lung Biopsy in Patients With Diffuse Interstitial Lung Disease","TOUCANS","Inclusion Criteria\n\n* Age 18-75 years\n* Diagnosed with diffuse ILD\n* Histological analysis required after standard diagnostic workup\n* Biopsy indication validated by MDD\n* Affiliated with French social security\n* Written informed consent Exclusion Criteria\n* Contraindication to SLB\n* Coagulation disorders\n* Significant comorbidities affecting safety\n* Long-term oxygen therapy\n* FVC \\\u003C55%, DLCO \\\u003C40%\n* BMI \\>35 kg\u002Fm²\n* Pulmonary hypertension (PAPS \\>40 mmHg)\n* Allergy to anesthetics\n* Protected populations (pregnant women, minors, legally protected adults)\n* β-HCG test required for non-menopausal women",{"count":681,"type":22},15,[25],"Rationale Interstitial lung diseases (ILDs) require accurate histological diagnosis when imaging is inconclusive, yet current techniques-surgical lung biopsy and transbronchial cryobiopsy-carry significant risks and lack real-time guidance. BPTE, widely used in oncology, provides ultrasound-guided sampling under local anesthesia with historically lower complication rates, but its value in ILD remains unproven. The TOUCANS study aims to generate safety and feasibility data to support its potential use as a less invasive diagnostic alternative.\n\nObjectives The primary objective is to assess the safety of BPTE in ILD patients, focusing on major adverse events: death, pneumothorax requiring drainage, hemorrhage requiring intervention, and prolonged pleural drainage. Secondary objectives include evaluating all complications within two months, comparing BPTE histological quality with surgical biopsy, and assessing pain, dyspnea, analgesic use, healing, drainage duration, and hematoma on thoracoscopic imaging.\n\nMaterials and Methods Fifteen patients aged 18-75 with ILD requiring tissue diagnosis after multidisciplinary review will be included. Exclusion criteria cover coagulation disorders, severe comorbidities, long-term oxygen therapy, impaired lung function, obesity, pulmonary hypertension, anesthetic allergy, and vulnerable populations. BPTE will be performed 2-4 weeks before surgical biopsy, under local anesthesia and spontaneous ventilation, with CT- and ultrasound-guided targeting. One or two biopsies will be taken, followed by ultrasound and chest X-ray monitoring; discharge occurs after four hours if stable. Surgical thoracoscopic biopsy will then be carried out with standard postoperative care. Pain, dyspnea, healing, and imaging findings will be recorded, and histological samples will be reviewed blindly. Data will be captured in eCRFs according to GDPR\u002FCNIL requirements.\n\nExpected Outcomes TOUCANS will provide the first prospective evidence on BPTE for ILD. Demonstrating safety and adequate diagnostic yield could position BPTE as a minimally invasive, outpatient, ultrasound-guided alternative to surgical biopsy. This may shorten diagnostic pathways, reduce complications, and offer a viable option for patients unsuitable for surgery, ultimately improving early management and prognosis.",[28],[28,686,687,688],"Transthoracic Ultrasound-Guided Biopsy (BPTE)","Safety Assessment","Histological Diagnosis","2025-12-11",{"date":691,"type":59},"2025-12-26",{"date":693,"type":22},"2025-12-15",{"date":695,"type":22},"2027-10",{"name":697,"class":66},"University Hospital, Tours"]